Tanios S. Bekaii-Saab, MD, FACP, Mayo Clinic

Metastatic Colorectal Cancer: Ongoing Challenges and Future Directions in Care

John Marshall, MD, Georgetown University Lombardi Comprehensive Cancer Center;Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center;Tanios S. Bekaii-Saab, MD, FACP, Mayo Clinic;Aparna R. Parikh, MD;Stacey A. Cohen, MD

July 26th 2023

Closing out their panel on metastatic colorectal cancer, expert oncologists consider ongoing challenges and future evolutions within the treatment landscape.

HER2+ Metastatic Colorectal Cancer: Clinical Trial Data With T-DXd

John Marshall, MD, Georgetown University Lombardi Comprehensive Cancer Center;Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center;Tanios S. Bekaii-Saab, MD, FACP, Mayo Clinic;Aparna R. Parikh, MD;Stacey A. Cohen, MD

July 19th 2023

Focused discussion on clinical trial data with trastuzumab deruxtecan in the setting of HER2+ metastatic colorectal cancer.

HER2+ Metastatic Colorectal Cancer: Clinical Trial Data With Tucatinib

John Marshall, MD, Georgetown University Lombardi Comprehensive Cancer Center;Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center;Tanios S. Bekaii-Saab, MD, FACP, Mayo Clinic;Aparna R. Parikh, MD;Stacey A. Cohen, MD

July 19th 2023

A panel of oncologists shares comprehensive insight to clinical trial data with tucatinib in patients with HER2+ metastatic colorectal cancer.

Assessing HER2 Expression in Metastatic Colorectal Cancer

John Marshall, MD, Georgetown University Lombardi Comprehensive Cancer Center;Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center;Tanios S. Bekaii-Saab, MD, FACP, Mayo Clinic;Aparna R. Parikh, MD;Stacey A. Cohen, MD

July 12th 2023

Switching their focus to HER2+ metastatic colorectal cancer, panelists discuss best practices in testing HER2 to aid in the timely selection of best available therapies.

Novel Combination Strategies in BRAF-Mutant Metastatic Colorectal Cancer

John Marshall, MD, Georgetown University Lombardi Comprehensive Cancer Center;Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center;Tanios S. Bekaii-Saab, MD, FACP, Mayo Clinic;Aparna R. Parikh, MD;Stacey A. Cohen, MD

July 12th 2023

Expert perspectives on novel combination and immunotherapy strategies within BRAF-mutated metastatic colorectal cancer management.

Metastatic Colorectal Cancer: Tumor Sidedness and EGFR-Targeted Therapy

John Marshall, MD, Georgetown University Lombardi Comprehensive Cancer Center;Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center;Tanios S. Bekaii-Saab, MD, FACP, Mayo Clinic;Aparna R. Parikh, MD;Stacey A. Cohen, MD

July 5th 2023

Shared insight to the importance of tumor sidedness and its impact on the selection of EGFR-targeted therapy in metastatic colorectal cancer.

BRAF V600E–Mutant Metastatic Colorectal Cancer: BREAKWATER Study

John Marshall, MD, Georgetown University Lombardi Comprehensive Cancer Center;Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center;Tanios S. Bekaii-Saab, MD, FACP, Mayo Clinic;Aparna R. Parikh, MD;Stacey A. Cohen, MD

July 5th 2023

Key opinion leaders in metastatic colorectal cancer management review data from the BREAKWATER study in BRAF-V600E–mutated disease.

Treatment Options for BRAF V600E–Mutant Metastatic Colorectal Cancer

John Marshall, MD, Georgetown University Lombardi Comprehensive Cancer Center;Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center;Tanios S. Bekaii-Saab, MD, FACP, Mayo Clinic;Aparna R. Parikh, MD;Stacey A. Cohen, MD

June 28th 2023

Centering discussion on patients with BRAF-V600E mutations in metastatic colorectal cancer, panelists reflect on the treatment armamentarium in this setting.

Colorectal Cancer: Evolving Role of ctDNA Testing in Practice

John Marshall, MD, Georgetown University Lombardi Comprehensive Cancer Center;Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center;Tanios S. Bekaii-Saab, MD, FACP, Mayo Clinic;Aparna R. Parikh, MD;Stacey A. Cohen, MD

June 28th 2023

A brief review of how circulating tumor DNA testing has impacted the real-world management of patients with metastatic colorectal cancer.

ctDNA and MRD Testing in Nonmetastatic Colorectal Cancer

John Marshall, MD, Georgetown University Lombardi Comprehensive Cancer Center;Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center;Tanios S. Bekaii-Saab, MD, FACP, Mayo Clinic;Aparna R. Parikh, MD;Stacey A. Cohen, MD

June 21st 2023

A focused discussion on the respective roles of circulating tumor DNA and minimal residual disease testing in the management of patients with nonmetastatic colorectal cancer.

Biomarker Testing in Metastatic Colorectal Cancer

John Marshall, MD, Georgetown University Lombardi Comprehensive Cancer Center;Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center;Tanios S. Bekaii-Saab, MD, FACP, Mayo Clinic;Aparna R. Parikh, MD;Stacey A. Cohen, MD

June 21st 2023

Expert panelists provide their perspective on the current state of molecular testing in metastatic colorectal cancer and how it impacts treatment pathways.

Optimizing Precision Medicine in HCC

Tanios S. Bekaii-Saab, MD, FACP, Mayo Clinic;Edward Kim, MD, Mount Sinai Medical Center;Anjana Pillai, MD, University of Chicago Medicine Comprehensive Cancer Center;Amit Singal, MD, UT Southwestern Medical Center;Rachna Shroff, MD, University of Arizona;Arndt Vogel, MD, Hannover Medical School;Mark Yarchoan, MD, Johns Hopkins Medicine

October 1st 2021

Takeaways from a discussion on treatment advances in hepatocellular carcinoma.

Biomarkers to Guide HCC Treatment Decisions

Tanios S. Bekaii-Saab, MD, FACP, Mayo Clinic;Edward Kim, MD, Mount Sinai Medical Center;Anjana Pillai, MD, University of Chicago Medicine Comprehensive Cancer Center;Amit Singal, MD, UT Southwestern Medical Center;Rachna Shroff, MD, University of Arizona;Arndt Vogel, MD, Hannover Medical School;Mark Yarchoan, MD, Johns Hopkins Medicine

October 1st 2021

Professionals who treat patients with hepatocellular carcinoma comment on the need for more research and biomarkers to fuel treatment decisions.

Second-Line Treatment Approaches for Advanced HCC

Tanios S. Bekaii-Saab, MD, FACP, Mayo Clinic;Edward Kim, MD, Mount Sinai Medical Center;Anjana Pillai, MD, University of Chicago Medicine Comprehensive Cancer Center;Amit Singal, MD, UT Southwestern Medical Center;Rachna Shroff, MD, University of Arizona;Arndt Vogel, MD, Hannover Medical School;Mark Yarchoan, MD, Johns Hopkins Medicine

September 24th 2021

An overview of the second-line treatment landscape for patients with advanced hepatocellular carcinoma and considerations regarding the sequencing of novel therapies.

The COSMIC-312 Study in Advanced HCC

Tanios S. Bekaii-Saab, MD, FACP, Mayo Clinic;Edward Kim, MD, Mount Sinai Medical Center;Anjana Pillai, MD, University of Chicago Medicine Comprehensive Cancer Center;Amit Singal, MD, UT Southwestern Medical Center;Rachna Shroff, MD, University of Arizona;Arndt Vogel, MD, Hannover Medical School;Mark Yarchoan, MD, Johns Hopkins Medicine

September 24th 2021

Thoughts regarding the COSMIC-312 study of cabozantinib plus atezolizumab as frontline therapy for advanced hepatocellular carcinoma.

HCC: IO in Liver Transplant Recipients

Tanios S. Bekaii-Saab, MD, FACP, Mayo Clinic;Edward Kim, MD, Mount Sinai Medical Center;Anjana Pillai, MD, University of Chicago Medicine Comprehensive Cancer Center;Amit Singal, MD, UT Southwestern Medical Center;Rachna Shroff, MD, University of Arizona;Arndt Vogel, MD, Hannover Medical School;Mark Yarchoan, MD, Johns Hopkins Medicine

September 17th 2021

A debate regarding the appropriateness of immunotherapy following liver transplantation in patients with hepatocellular carcinoma.

The LEGACY Study in HCC

Tanios S. Bekaii-Saab, MD, FACP, Mayo Clinic;Edward Kim, MD, Mount Sinai Medical Center;Anjana Pillai, MD, University of Chicago Medicine Comprehensive Cancer Center;Amit Singal, MD, UT Southwestern Medical Center;Rachna Shroff, MD, University of Arizona;Arndt Vogel, MD, Hannover Medical School;Mark Yarchoan, MD, Johns Hopkins Medicine

September 17th 2021

Implications on treatment practices of the LEGACY study of Y-90 glass microspheres in patients with unresectable solitary hepatocellular carcinoma.

Selecting First-Line Therapy for Advanced HCC

Tanios S. Bekaii-Saab, MD, FACP, Mayo Clinic;Edward Kim, MD, Mount Sinai Medical Center;Anjana Pillai, MD, University of Chicago Medicine Comprehensive Cancer Center;Amit Singal, MD, UT Southwestern Medical Center;Rachna Shroff, MD, University of Arizona;Arndt Vogel, MD, Hannover Medical School;Mark Yarchoan, MD, Johns Hopkins Medicine

September 10th 2021

An overview of factors that deem patients appropriate for atezolizumab/bevacizumab vs lenvatinib or sorafenib as frontline therapy for advanced hepatocellular carcinoma.

Frontline IO for Advanced HCC

Tanios S. Bekaii-Saab, MD, FACP, Mayo Clinic;Edward Kim, MD, Mount Sinai Medical Center;Anjana Pillai, MD, University of Chicago Medicine Comprehensive Cancer Center;Amit Singal, MD, UT Southwestern Medical Center;Rachna Shroff, MD, University of Arizona;Arndt Vogel, MD, Hannover Medical School;Mark Yarchoan, MD, Johns Hopkins Medicine

September 10th 2021

Considerations regarding the use of nivolumab as frontline treatment for advanced hepatocellular carcinoma.

Systemic Treatment Advances for Advanced HCC

Tanios S. Bekaii-Saab, MD, FACP, Mayo Clinic;Edward Kim, MD, Mount Sinai Medical Center;Anjana Pillai, MD, University of Chicago Medicine Comprehensive Cancer Center;Amit Singal, MD, UT Southwestern Medical Center;Rachna Shroff, MD, University of Arizona;Arndt Vogel, MD, Hannover Medical School;Mark Yarchoan, MD, Johns Hopkins Medicine

September 3rd 2021

Exciting developments using novel therapies as systemic treatment for advanced hepatocellular carcinoma.

Scoring/Classifying Patients With Advanced HCC

Tanios S. Bekaii-Saab, MD, FACP, Mayo Clinic;Edward Kim, MD, Mount Sinai Medical Center;Anjana Pillai, MD, University of Chicago Medicine Comprehensive Cancer Center;Amit Singal, MD, UT Southwestern Medical Center;Rachna Shroff, MD, University of Arizona;Arndt Vogel, MD, Hannover Medical School;Mark Yarchoan, MD, Johns Hopkins Medicine

September 3rd 2021

Best practices using available scoring systems to evaluate and treat patients with advanced hepatocellular carcinoma.

Adjuvant Treatment Advances in Operable HCC

Tanios S. Bekaii-Saab, MD, FACP, Mayo Clinic;Edward Kim, MD, Mount Sinai Medical Center;Anjana Pillai, MD, University of Chicago Medicine Comprehensive Cancer Center;Amit Singal, MD, UT Southwestern Medical Center;Rachna Shroff, MD, University of Arizona;Arndt Vogel, MD, Hannover Medical School;Mark Yarchoan, MD, Johns Hopkins Medicine

August 27th 2021

Perspectives regarding treatment advances using adjuvant approaches that include immunotherapy to treat early-stage hepatocellular carcinoma.

Hepatic Arterial Infusion Chemotherapy for HCC

Tanios S. Bekaii-Saab, MD, FACP, Mayo Clinic;Edward Kim, MD, Mount Sinai Medical Center;Anjana Pillai, MD, University of Chicago Medicine Comprehensive Cancer Center;Amit Singal, MD, UT Southwestern Medical Center;Rachna Shroff, MD, University of Arizona;Arndt Vogel, MD, Hannover Medical School;Mark Yarchoan, MD, Johns Hopkins Medicine

August 27th 2021

Reactions to recent clinical abstracts that support the use of hepatic arterial infusions for chemotherapy delivery in hepatocellular carcinoma.

Neoadjuvant Therapy to Downstage HCC

Tanios S. Bekaii-Saab, MD, FACP, Mayo Clinic;Edward Kim, MD, Mount Sinai Medical Center;Anjana Pillai, MD, University of Chicago Medicine Comprehensive Cancer Center;Amit Singal, MD, UT Southwestern Medical Center;Rachna Shroff, MD, University of Arizona;Arndt Vogel, MD, Hannover Medical School;Mark Yarchoan, MD, Johns Hopkins Medicine

August 20th 2021

Reactions to treatment gaps in the neoadjuvant space for hepatocellular carcinoma and implications for incorporating data supporting newer, novel systemic therapies for appropriate patients.

Advances in Locoregional Therapy for Early Stage HCC

Tanios S. Bekaii-Saab, MD, FACP, Mayo Clinic;Edward Kim, MD, Mount Sinai Medical Center;Anjana Pillai, MD, University of Chicago Medicine Comprehensive Cancer Center;Amit Singal, MD, UT Southwestern Medical Center;Rachna Shroff, MD, University of Arizona;Arndt Vogel, MD, Hannover Medical School;Mark Yarchoan, MD, Johns Hopkins Medicine

August 20th 2021

University of Arizona’s Rachna Shroff, MD, describes the role of systemic therapy with locoregional treatment for early stage hepatocellular carcinoma and highlights treatment strategies of interest that remain under investigation.

Current Role of Locoregional Therapy for Early Stage HCC

Tanios S. Bekaii-Saab, MD, FACP, Mayo Clinic;Edward Kim, MD, Mount Sinai Medical Center;Anjana Pillai, MD, University of Chicago Medicine Comprehensive Cancer Center;Amit Singal, MD, UT Southwestern Medical Center;Rachna Shroff, MD, University of Arizona;Arndt Vogel, MD, Hannover Medical School;Mark Yarchoan, MD, Johns Hopkins Medicine

August 13th 2021

Edward Kim, MD, of Mount Sinai Health System describes where advances in locoregional therapy for early-stage hepatocellular carcinoma fit into the therapeutic landscape.